^
    TruSight Oncology 500 ctDNA v2 is a pan-cancer NGS assay that enables in-house comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) in blood plasma for research. The assay target 523 genes to assess DNA variants across major variant classes (SNV, MNV, indels, CNV, and gene rearrangements), plus key immuno-oncology gene signatures (TMB, MSI).
    Cancer:
    Solid Tumor
    Gene:
    MSI (Microsatellite instability), TMB (Tumor Mutational Burden)
    Method:
    Next-Generation Sequencing (NGS) / Circulating tumor DNA (ctDNA)